Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT-2: Macitentan in Inoperable CTEPH
NCT02060721Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2015
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Feb 2015; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT02060721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060721.